TechBiolevate raises €30 million Series A to expand its life sciences AI platform
Tech.eu reports that RAISE France and Orange Ventures co-led the round. Axios says the Paris-based company is using the capital primarily to expand in the U.S.
TLDR
Biolevate raised €30 million in a Series A co-led by RAISE France and Orange Ventures, Tech.eu reports. Other participants included MSD Global Health Innovation Fund, Station F and existing investor EQT Ventures. Tech.eu describes the platform as designed to automate scientific and regulatory workflows while keeping outputs grounded in source evidence and maintaining human oversight. Axios reports that the capital is primarily for U.S. expansion, and Tech.eu says Biolevate is opening an office in Boston.
Combined views
—
First seen 6h ago
Biolevate raises €30 million Series A to expand its life sciences AI platform
Tech.eu reports that RAISE France and Orange Ventures co-led the round. Axios says the Paris-based company is using the capital primarily to expand in the U.S.
TLDR
Biolevate raised €30 million in a Series A co-led by RAISE France and Orange Ventures, Tech.eu reports. Other participants included MSD Global Health Innovation Fund, Station F and existing investor EQT Ventures. Tech.eu describes the platform as designed to automate scientific and regulatory workflows while keeping outputs grounded in source evidence and maintaining human oversight. Axios reports that the capital is primarily for U.S. expansion, and Tech.eu says Biolevate is opening an office in Boston.